IP Library › Granted Patent US 10,266,574
Granted Patent B2
US 10,266,574 · App. 14/313,694 · Granted Apr 23, 2019

Tuberculosis compositions and methods of using the same

Inventors: Ravi Anantha (Rockville, MD); Nathalie Cadieux (Rockville, MD); Thomas G. Evans (Rockville, MD); Michele Stone (Rockville, MD); Barry Walker (Rockville, MD)
Assignee: International AIDS Vaccine Initiative, Inc.
C07K14/35A61K39/04A61K2039/523A61K2039/545A61K2039/55561A61K2039/55572A61K2039/70C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,266,574
App. No.
14/313,694
Granted
Apr 23, 2019
Kind
B2
Abstract

The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.

Claims (24)

1. A fusion protein consisting of four or five antigens, wherein the four or five antigens are Mycobacterium tuberculosis antigens, and wherein the fusion protein comprises an amino acid sequence that is at least 98% identical to an amino acid sequence of:

ESAT6-Rv1733c-Rv2626c-RpfD (SEQ ID NO:53 or SEQ ID NO:54);

ESAT6-Rv1733c-Rv2626c-RpfB (SEQ ID NO:56);

RpfB-ESAT6-Rv1733c-Rv2626c (SEQ ID NO:58);

Ag85B-ESAT6-Rv1733c-Rv2626c-RpfD (SEQ ID NO:61 or SEQ ID NO:62);

Ag85B-ESAT6-Rv1733c-Rv2626c-RpfB (SEQ ID NO:99 or SEQ ID NO:100);

PPE51-Rv1733c-Rv2628c-RpfD (SEQ ID NO:64);

PPE51-Rv1733c-Rv2628c-RpfB (SEQ ID NO:66);

Rv3407-Rv1733c-Rv2626c-RpfB (SEQ ID NO:68); or

Rv3407-Rv1733c-Rv2626c-RpfD (SEQ ID NO:70).

2. A pharmaceutical composition comprising the fusion protein according to claim 1 and a pharmaceutically acceptable carrier.

3. The fusion protein according to claim 1 , wherein the fusion protein comprises an amino acid sequence at least 98% identical to an amino acid sequence of Ag85B-ESAT6-Rv1733c-Rv2626c-RpfD (SEQ ID NO:61 or SEQ ID NO:62).

4. A fusion protein selected from the group consisting of

ESAT6-Rv1733c-Rv2626c-RpfD (SEQ ID NO:53 or SEQ ID NO:54);

ESAT6-Rv1733c-Rv2626c-RpfB (SEQ ID NO:56);

RpfB-ESAT6-Rv1733c-Rv2626c (SEQ ID NO:58);

Ag85B-ESAT6-Rv1733c-Rv2626c-RpfD (SEQ ID NO:61 or SEQ ID NO:62);

Ag85B-ESAT6-Rv1733c-Rv2626c-RpfB (SEQ ID NO:99 or SEQ ID NO:100);

PPE51-Rv1733c-Rv2628c-RpfD (SEQ ID NO:64);

PPE51-Rv1733c-Rv2628c-RpfB (SEQ ID NO:66);

Rv3407-Rv1733c-Rv2626c-RpfB (SEQ ID NO:68); or

Rv3407-Rv1733c-Rv2626c-RpfD (SEQ ID NO:70).

5. The fusion protein according to claim 4 , where in the fusion protein is Ag85B-ESAT6-Rv1733c-Rv2626c-RpfD (SEQ ID NO:61 or SEQ ID NO:62).

6. A method of eliciting an immune response against Mycobacterium tuberculosis in a mammal comprising administering to the mammal an immunologically sufficient amount of the fusion protein according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: AERAS
To: INTERNATIONAL AIDS VACCINE INITIATIVE, INC.
Reel/Frame 047292/0924 →
CHANGE OF NAME Recorded Dec 27, 2016
From: AERAS GLOBAL TB VACCINE FOUNDATION
To: AERAS
Reel/Frame 041303/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2014
From: ANANTHA, RAVI; CADIEUX, NATHALIE; EVANS, THOMAS G.; STONE, MICHELE; WALKER, BARRY
To: AERAS GLOBAL TB VACCINE FOUNDATION
Reel/Frame 034167/0242 →
Continuity (2)
Provisional Application 61838872 · Jun 25, 2013
Related Publication 20140377300A1 · Dec 25, 2014